Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 June 2025 | Story Andre Damons | Photo Andre Damons
Prof Matlalepula Matsabisa
Prof Motlalepula Matsabisa, renowned African Traditional Medicine expert and pharmacology researcher from the University of the Free State (UFS) will co-chair the World Health Organisation Global Traditional Medicine Summit steering committee.

Prof Motlalepula Matsabisa, renowned African Traditional Medicine expert and pharmacology researcher from the University of the Free State (UFS) has recently been elected a co-chairperson of the World Health Organisation (WHO) Global Traditional Medicine Summit steering committee. The other co-chairperson is Dr Goh Cheng Soon from Malaysia. 

The steering committee, which is appointed for one year, will help the WHO to organise the WHO Traditional Medicines Global Summit taking place later this year in New Delhi, India. The steering committee is also an advisory body to the WHO and the Global Traditional Medicine Centre to provide reviews and recommendations for the WHO Traditional Medicine Global Summit coordination, propose summit sessions and session speakers. This committee has 15 members from South Africa, Malaysia, Saudi Arabia, Ghana, India, China, Bhutan, Germany, Brazil, Egypt, New Zealand, US, Netherlands, Switzerland and Bolivia.

Prof Matsabisa, Research Director of the African Medicines Innovations and Technologies Development (AMITD) platform at the UFS, is also the chairperson of the WHO Africa Regional Expert Advisory Committee on Traditional Medicine (REACT)

 

Responsibility of the committee 

“Once more this is an honour for me to take this task and lead a group of experts – not just from the African continent where I am currently the chairperson of the WHO Afro REACT committee, but now I chair experts from all the continents and all six WHO geographical regions – namely Africa (Afro), the Americas (AMRO), the eastern Mediterranean (EMRO), Europe (EURO), South East Asia (SEARO) and the Western Pacific (WPRO). I chair a worldwide group of experts,” says Prof Matsabisa. 

According to him, the committee will work with WHO to design the summit programme, identify summit sessions and session speakers, as well as recommend ministers to be in the round-table discussions. The committee will also be responsible for the design of the exhibitions that will showcase traditional medicine products and practices across all six WHO regions. The identification of the sessions will be around action and delivery on the priority agenda from the past 2023 WHO Global summit as well as from the deliverables of the WHO 2025-2034 Traditional Medicines strategy. 

The theme for the WHO Traditional Medicines Global Summit is “Restoring balance for people and planet. The science and practice of health and well-being”. They anticipate attracting 6 000 people, from all over, to attend the summit with at least 1 000 in-person attendees and another 5 000 online participants. 

The committee will look at the first WHO 2023 Traditional Medicines Global summit and its Gujarat Declaration where the Traditional Medicine (TM) priority agenda was set – this priority agenda included global leadership, research and evidence, universal health coverage (UHC), primary health care (PHC) health systems, data and routine information systems, biodiversity and sustainability.

 

Market the UFS 

When a call for applications to serve on the steering committee went out, Prof Matsabisa applied and was later approached by the WHO to chair the steering and advisory committee. “I see this as an opportunity to serve the WHO and use my knowledge and skills to serve the world. I felt very honoured to have been approached for such an important job and role to undertake. As a chairperson, I will guide the committee, take responsibility for the planning and implementation of the summit. I will market the summit. I shall be the direct link between the WHO in Geneva and the committee.”

Prof Matsabisa indicated that he will use the chairmanship to market and internationalise the UFS AMITD programme and give it a further global outlook. He will also find new collaborators and potential funders and investors for projects and activities of the UFS and secure activities that will help find and fund global postdoctoral fellows and visiting scholars. This will be good for the AMITD platform.

“The steering committee shall set the 2nd WHO Traditional Medicine Global Summit theme for scale up learning, collaboration and action,” says Prof Matsabisa. “Therefore, the committee will design the summit programme to address these and take themes and discussions from high-level political commitments, building on UNGA, WHA, G20, BRICS, and AU etc. Launches of the WHO Global TM Library on Traditional Medicine; WHO Bulletin special issue on Traditional Medicine; TM Innovation and Investment Initiative; Global TM Research Roadmap; Global TM Data Network; and Learnings from Indigenous Knowledge will also take place.”

Furthermore, advancements of healthy ecosystems and TM integration and encouraging indigenous people's knowledge exchange; and AI and TM governance course/ brief as well as the advancing of cross-cutting frameworks for TM-related ethics, rights, IP, equitable access and benefits are on the agenda. 

News Archive

Research eradicates bacteria from avocado facility
2017-01-17

 Description: Listeria monocytogenes Tags: Listeria monocytogenes

Listeria monocytogenes as seen under an electron
microscope. The photo was taken with a transmission
electron microscope at the microscopy unit of the UFS.
Bacteriophages (lollipop-like structures) can be seen
next to the bacterial cells.
Photo: Supplied

“The aim of my project was to identify and characterise the contamination problem in an avocado-processing facility and then to find a solution,” said Dr Amy Strydom, postdoctoral fellow in the Department of Microbial Biochemical and Food Biotechnology at the University of the Free State (UFS).

Her PhD, “Control of Listeria monocytogenes in an Avocado-processing Facility”, aimed to identify and characterise the contamination problem in a facility where avocados were processed into guacamole. Dr Strydom completed her MSc in food science in 2009 at Stellenbosch University and this was the catalyst for her starting her PhD in microbiology in 2012 at the UFS. The research was conducted over a period of four years and she graduated in 2016. The research project was funded by the National Research Foundation.

The opportunity to work closely with the food industry further motivated Dr Strydom to conduct her research. The research has made a significant contribution to a food producer (avocado facility) that will sell products that are not contaminated with any pathogens. The public will then buy food that is safe for human consumption.


What is Listeria monocytogenes?

Listeria monocytogenes is a food-borne pathogenic bacterium. When a food product is contaminated with L. monocytogenes, it will not be altered in ways that are obvious to the consumer, such as taste and smell. When ingested, however, it can cause a wide range of illnesses in people with impaired immune systems. “Risk groups include newborn babies, the elderly, and people suffering from diseases that weaken their immune systems,” Dr Strydom said. The processing adjustments based on her findings resulted in decreased numbers of Listeria in the facility.

The bacteria can also survive and grow at refrigeration temperatures, making them dangerous food pathogens, organisms which can cause illnesses [in humans]. Dr Strydom worked closely with the facility and developed an in-house monitoring system by means of which the facility could test their products and the processing environment. She also evaluated bacteriophages as a biological control agent in the processing facility. Bacteriophages are viruses that can only infect specific strains of bacteria. Despite bacteriophage products specifically intended for the use of controlling L. monocytogenes being commercially available in the food industry, Dr Strydom found that only 26% of the L. monocytogenes population in the facility was destroyed by the ListexP100TM product. “I concluded that the genetic diversity of the bacteria in the facility was too high and that the bacteriophages could not be used as a control measure. However, there is much we do not understand about bacteriophages, and with a few adjustments, we might be able to use them in the food industry.”

Microbiological and molecular characterisation of L. monocytogenes

The bacteria were isolated and purified using basic microbiological culturing. Characterisation was done based on specific genes present in the bacterial genome. “I amplified these genes with polymerase chain reaction (PCR), using various primers targeting these specific genes,” Dr Strydom said. Some amplification results were analysed with a subsequent restriction digestion where the genes were cut in specific areas with enzymes to create fragments. The lengths of these fragments can be used to differentiate between strains. “I also compared the whole genomes of some of the bacterial strains.” The bacteriophages were then isolated from waste water samples at the facility using the isolated bacterial strains. “However, I was not able to isolate a bacteriophage that could infect the bacteria in the facility.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept